Those include Sunlenca, which is approved for resistant HIV as a twice-yearly injection after an initial oral regimen, and ...
Gilead and Merck & Co. have guided their once-weekly HIV combination therapy past another milestone, linking the cocktail to ...
GILD and partner MRK advance novel investigational combination regimen, a weekly oral HIV treatment, to phase III.
Lenacapavir is a long-acting pre-exposure prophylaxis (PrEP) product, a treatment that works by stopping HIV from getting ...
EDP-323 is an investigational inhibitor of Respiratory Syncytial Virus (RSV), currently showing promising results in Phase 2a ...
Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...
From oral PrEP, to injectables, rings, and implants, this year's HIV Research for Prevention conference was all about options ...
Blog - allAfrica's Sethi Ncube is in Lima, Peru, for the 5th HIV Research for Prevention Conference, HIVR4P 2024, reporting ...
It is just as safe and effective for people with HIV in need of kidney transplantation to get their organ from donors who are also HIV positive as it is from donors who are not infected with the virus ...
Kidney transplants between people with HIV are safe and effective, according to a new study. The procedure should be expanded ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback